Compare · BSGM vs MDT
BSGM vs MDT
Side-by-side comparison of BioSig Technologies Inc. (BSGM) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSGM and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $94.69B, about 1625.2x BSGM ($58.3M).
- Over the past year, BSGM is down 5.2% and MDT is down 13.9% - BSGM leads by 8.7 points.
- MDT has hit the wire 13 times in the past 4 weeks while BSGM has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 0 for BSGM).
- Company
- BioSig Technologies Inc.
- Medtronic plc.
- Price
- $6.11+36.69%
- $73.72-0.34%
- Market cap
- $58.3M
- $94.69B
- 1M return
- +31.40%
- -7.84%
- 1Y return
- -5.20%
- -13.86%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
BioSig Technologies Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BSGM
- Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs
- Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)
- SEC Form 3 filed by new insider Giustra Frank
- Amendment: SEC Form SCHEDULE 13G/A filed by BioSig Technologies Inc.
- SEC Form DEFA14A filed by BioSig Technologies Inc.
- BioSig Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.
- Monetary Metals Enters into Exclusive Partnership with Streamex (Nasdaq: BSGM) to Create Tokenized Yield-Bearing Gold Products
- BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
Latest MDT
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip converted options into 15,195 units of Ordinary Shares, increasing direct ownership by 46% to 48,233 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. converted options into 1,712 units of Ordinary Shares, increasing direct ownership by 13% to 14,974 units (SEC Form 4)
- SEC Form SD filed by Medtronic plc.
- Goldman resumed coverage on Medtronic with a new price target
- Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain